Dorothea Rudolph

Dorothea Rudolph

Auto-generated profile, based on publicly available information

Dorothea Rudolph

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
ATAntonio Tedeschi
Antonio Tedeschi
FSFiorella Schischlik
Fiorella Schischlik
FRFrancesca Rocchetti
Francesca Rocchetti
JPJohannes Popow
Johannes Popow
FEFlorian Ebner
Florian Ebner
DRDorothea Rudolph
Dorothea Rudolph
KRASG12C selective inhibitors, such as sotorasib and adagrasib, have raised hopes of targeting other KRAS-mutant alleles in patients with cancer. We report that KRAS wild-type (WT)–amplified tumor models are sensitive to treatment with the small-molecule KRAS inhibitors BI-2493 and BI-2865. These pan-KRAS inhibitors directly target the “OFF” state of KRAS and result in potent antitumor activity in preclinical models of cancers driven by KRAS-mutant proteins. In this study, we used the high-throughput cellular viability Profiling Relative Inhibition Simultaneously in Mixtures assay to assess the antiproliferative activity of BI-2493 in a 900+ cancer cell line panel, expanding on our previous work. KRAS WT–amplified cancer cell lines, with a copy number >7, were identified as the most sensitive, across cell lines with any KRAS alterations, to our pan-KRAS inhibitors. Importantly, our data suggest that a KRAS “OFF” inhibitor is better suited to treat KRAS WT–amplified tumors than a KRAS “ON” inhibitor. KRAS WT amplification is common in patients with gastroesophageal cancers in which it has been shown to act as a unique cancer driver with little overlap to other actionable mutations. The pan-KRAS inhibitors BI-2493 and BI-2865 show potent antitumor activity in vitro and in vivo in KRAS WT–amplified cell lines from this and other tumor types. In conclusion, this is the first study to demonstrate that direct pharmacologic inhibition of KRAS shows antitumor activity in preclinical models of cancer with KRAS WT amplification, suggesting a novel therapeutic concept for patients with cancers bearing this KRAS alteration.

11 September 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
AGAndreas Gollner
Andreas Gollner
DRDorothea Rudolph
Dorothea Rudolph
UWUlrike Weyer-Czernilofsky
Ulrike Weyer-Czernilofsky
RBRosa Baumgartinger
Rosa Baumgartinger
PJPeter Jung
Peter Jung
PSPatrizia Sini
Patrizia Sini
P53 is known as the guardian of the genome and is one of the most important tumor suppressors. It is inactivated in most tumors, either via tumor protein p53 (TP53) gene mutation or copy number amplification of key negative regulators, e.g., mouse double minute 2 (MDM2). Compounds that bind to the MDM2 protein and disrupt its interaction with p53 restore p53 tumor suppressor activity, thereby promoting cell cycle arrest and apoptosis. Previous clinical experience with MDM2–p53 protein–protein interaction antagonists (MDM2–p53 antagonists) has demonstrated that thrombocytopenia and neutropenia represent on-target dose-limiting toxicities that might restrict their therapeutic utility. Dosing less frequently, while maintaining efficacious exposure, represents an approach to mitigate toxicity and improve the therapeutic window of MDM2–p53 antagonists. However, to achieve this, a molecule possessing excellent potency and ideal pharmacokinetic properties is required. Here, we present the discovery and characterization of brigimadlin (BI 907828), a novel, investigational spiro-oxindole MDM2–p53 antagonist. Brigimadlin exhibited high bioavailability and exposure, as well as dose-linear pharmacokinetics in preclinical models. Brigimadlin treatment restored p53 activity and led to apoptosis induction in preclinical models of TP53 wild-type, MDM2-amplified cancer. Oral administration of brigimadlin in an intermittent dosing schedule induced potent tumor growth inhibition in several TP53 wild-type, MDM2-amplified xenograft models. Exploratory clinical pharmacokinetic studies (NCT03449381) showed high systemic exposure and a long plasma elimination half-life in patients with cancer who received oral brigimadlin. These findings support the continued clinical evaluation of brigimadlin in patients with MDM2-amplified cancers, such as dedifferentiated liposarcoma.

1 October 2008 in European Journal of Cancer Supplements
Verified
Journal Article
Closed access
DRD. Rudolph
D. Rudolph
MSM. Steegmaier
M. Steegmaier
MHM. Hoffmann
M. Hoffmann
MGM. Grauert
M. Grauert
ABA. Baum
A. Baum
GAG. Adolf
G. Adolf



2 April 2025
Verified
Other
Open access
PDF file
ATAntonio Tedeschi
Antonio Tedeschi
FSFiorella Schischlik
Fiorella Schischlik
FRFrancesca Rocchetti
Francesca Rocchetti
JPJohannes Popow
Johannes Popow
FEFlorian Ebner
Florian Ebner
DRDorothea Rudolph
Dorothea Rudolph
Supplementary Figure 4. Correlation between signatures for KRAS activation and sensitivity to BI-2493 across the KRAS wild-type amplified cell panel. RAS activation signatures were obtained from East et al. (1). Correlation coefficient between enrichment scores and sensitivity to BI-2493 were estimated using a Pearson R.